bioAffinity reports April CyPath Lung unit sales jump nearly 300% year over year

bioAffinity

bioAffinity

BIAF

0.00
  • bioAffinity Technologies reported record monthly unit sales for CyPath Lung in April 2026, based on preliminary unaudited data.
  • CyPath Lung unit sales rose nearly 300% from April 2025, exceeding internal projections.
  • Growth was attributed to accelerating physician adoption, expansion of ordering sites, and deeper integration into clinical workflows for lung cancer risk assessment and pulmonary nodule management.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605120915BIZWIRE_USPR_____20260512_BW770887) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.